"A slow start for self-amplifying mRNA vaccines" was originally created and published by Pharmaceutical Technology, a ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...

Japan is the first country to put a self-amplifying mRNA vaccine into practical use. The health ministry’s expert committee that approved the replicon vaccine has said, “It is desirable to ...

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 Meiji Seika Pharma Co., Ltd. (Headquarters ...

a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The primary objective of this ...

In contrast, saRNA delivered into a cell first self-amplifies, resulting in very high mRNA copy numbers, thereby achieving superior gene expression and an amplified protein response with a much ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...

Unlike standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response.

With its focus on self-amplifying mRNA (SAM-RNA) technology and strategic partnerships, Arcturus aims to differentiate itself in the lucrative vaccine market while advancing its therapeutic pipeline.